ACAD vs RADX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACAD Captures Institutional Edge (3โ1 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical while RADX counters with relative strength in Options & Structure. Fundamentally, ACAD trades at 15.8x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus RADX at N/M Forward P/E and -411.6% operating margin (-36.9% YoY). In options structure, ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against RADX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACAD | RADX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $10.6M | Larger Scale | ACAD |
| Trailing P/E Ratio Valuation | 8.3x | N/M | Lower Multiple | ACAD |
| Forward P/E Ratio Valuation | 15.8x | N/M | Lower Multiple | ACAD |
| Revenue Growth (YoY) Growth | +22.8% | -36.9% | Higher Growth | ACAD |
| Operating Margin (TTM) Profitability | 10.2% | -411.6% | Higher Margin | ACAD |
| Net Profit Margin Profitability | 30.1% | 0.0% | Higher Margin | ACAD |
| Return on Equity (ROE) Capital Efficiency | 31.4% | -174.7% | Higher ROE | ACAD |
| 52-Week Range Position Momentum | 8% ($16โ$31) | 0% ($1โ$16) | Stronger Trend | ACAD |
| Beta / 30D Volatility Risk Regime | 0.15ฮฒ ยท 90% Vol | 0.52ฮฒ ยท 109% Vol | Lower Realized Risk | ACAD |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 41.1 / 100 (SELL) | Higher Composite | ACAD |